166 related articles for article (PubMed ID: 37435859)
1. LRP8-mediated selenocysteine uptake is a targetable vulnerability in MYCN-amplified neuroblastoma.
Alborzinia H; Chen Z; Yildiz U; Freitas FP; Vogel FCE; Varga JP; Batani J; Bartenhagen C; Schmitz W; Büchel G; Michalke B; Zheng J; Meierjohann S; Girardi E; Espinet E; Flórez AF; Dos Santos AF; Aroua N; Cheytan T; Haenlin J; Schlicker L; Xavier da Silva TN; Przybylla A; Zeisberger P; Superti-Furga G; Eilers M; Conrad M; Fabiano M; Schweizer U; Fischer M; Schulze A; Trumpp A; Friedmann Angeli JP
EMBO Mol Med; 2023 Aug; 15(8):e18014. PubMed ID: 37435859
[TBL] [Abstract][Full Text] [Related]
2.
Floros KV; Cai J; Jacob S; Kurupi R; Fairchild CK; Shende M; Coon CM; Powell KM; Belvin BR; Hu B; Puchalapalli M; Ramamoorthy S; Swift K; Lewis JP; Dozmorov MG; Glod J; Koblinski JE; Boikos SA; Faber AC
Cancer Res; 2021 Apr; 81(7):1896-1908. PubMed ID: 33483374
[No Abstract] [Full Text] [Related]
3. MYCN mediates TFRC-dependent ferroptosis and reveals vulnerabilities in neuroblastoma.
Lu Y; Yang Q; Su Y; Ji Y; Li G; Yang X; Xu L; Lu Z; Dong J; Wu Y; Bei JX; Pan C; Gu X; Li B
Cell Death Dis; 2021 May; 12(6):511. PubMed ID: 34011924
[TBL] [Abstract][Full Text] [Related]
4. MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis.
Alborzinia H; Flórez AF; Kreth S; Brückner LM; Yildiz U; Gartlgruber M; Odoni DI; Poschet G; Garbowicz K; Shao C; Klein C; Meier J; Zeisberger P; Nadler-Holly M; Ziehm M; Paul F; Burhenne J; Bell E; Shaikhkarami M; Würth R; Stainczyk SA; Wecht EM; Kreth J; Büttner M; Ishaque N; Schlesner M; Nicke B; Stresemann C; Llamazares-Prada M; Reiling JH; Fischer M; Amit I; Selbach M; Herrmann C; Wölfl S; Henrich KO; Höfer T; Trumpp A; Westermann F
Nat Cancer; 2022 Apr; 3(4):471-485. PubMed ID: 35484422
[TBL] [Abstract][Full Text] [Related]
5. Ribosome stalling during selenoprotein translation exposes a ferroptosis vulnerability.
Li Z; Ferguson L; Deol KK; Roberts MA; Magtanong L; Hendricks JM; Mousa GA; Kilinc S; Schaefer K; Wells JA; Bassik MC; Goga A; Dixon SJ; Ingolia NT; Olzmann JA
Nat Chem Biol; 2022 Jul; 18(7):751-761. PubMed ID: 35637349
[TBL] [Abstract][Full Text] [Related]
6. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
7. Catastrophic ATP loss underlies a metabolic combination therapy tailored for
Dalton KM; Lochmann TL; Floros KV; Calbert ML; Kurupi R; Stein GT; McClanaghan J; Murchie E; Egan RK; Greninger P; Dozmorov M; Ramamoorthy S; Puchalapalli M; Hu B; Shock L; Koblinski J; Glod J; Boikos SA; Benes CH; Faber AC
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33762304
[No Abstract] [Full Text] [Related]
8. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma.
Arlt B; Zasada C; Baum K; Wuenschel J; Mastrobuoni G; Lodrini M; Astrahantseff K; Winkler A; Schulte JH; Finkler S; Forbes M; Hundsdoerfer P; Guergen D; Hoffmann J; Wolf J; Eggert A; Kempa S; Deubzer HE
Int J Cancer; 2021 Mar; 148(5):1219-1232. PubMed ID: 33284994
[TBL] [Abstract][Full Text] [Related]
10. DNA Ligase 4 Contributes to Cell Proliferation against DNA-PK Inhibition in
Ando K; Suenaga Y; Kamijo T
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240360
[TBL] [Abstract][Full Text] [Related]
11. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors.
Petroni M; Sardina F; Infante P; Bartolazzi A; Locatelli E; Fabretti F; Di Giulio S; Capalbo C; Cardinali B; Coppa A; Tessitore A; Colicchia V; Sahùn Roncero M; Belardinilli F; Di Marcotullio L; Soddu S; Comes Franchini M; Petricci E; Gulino A; Giannini G
Cell Death Dis; 2018 Aug; 9(9):895. PubMed ID: 30166519
[TBL] [Abstract][Full Text] [Related]
12. Combining inhibitors of Brd4 and cyclin-dependent kinase can decrease tumor growth in neuroblastoma with MYCN amplification.
Wood L; Huang M; Zeki J; Gong M; Taylor J; Shimada H; Chiu B
J Pediatr Surg; 2021 Jul; 56(7):1199-1202. PubMed ID: 33838899
[TBL] [Abstract][Full Text] [Related]
13. Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration.
Zaatiti H; Abdallah J; Nasr Z; Khazen G; Sandler A; Abou-Antoun TJ
Int J Oncol; 2018 Mar; 52(3):787-803. PubMed ID: 29328367
[TBL] [Abstract][Full Text] [Related]
14. The super elongation complex drives transcriptional addiction in
Wang D; Yin Z; Wang H; Wang L; Li T; Xiao R; Xie T; Han R; Dong R; Liu H; Liang K; Qing G
Sci Adv; 2023 Mar; 9(13):eadf0005. PubMed ID: 36989355
[No Abstract] [Full Text] [Related]
15. Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation.
Newman EA; Chukkapalli S; Bashllari D; Thomas TT; Van Noord RA; Lawlor ER; Hoenerhoff MJ; Opipari AW; Opipari VP
Cell Death Dis; 2017 Dec; 8(12):3208. PubMed ID: 29238067
[TBL] [Abstract][Full Text] [Related]
16. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase.
Veas-Perez de Tudela M; Delgado-Esteban M; Cuende J; Bolaños JP; Almeida A
J Neurochem; 2010 May; 113(4):819-25. PubMed ID: 20180881
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[
Li C; Huang S; Guo J; Wang C; Huang Z; Huang R; Liu L; Liang S; Wang H
Mol Imaging Biol; 2019 Dec; 21(6):1117-1126. PubMed ID: 30850970
[TBL] [Abstract][Full Text] [Related]
18. Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC-Driven Cancer Progression.
Gao J; Jung M; Mayoh C; Venkat P; Hannan KM; Fletcher JI; Kamili A; Gifford AJ; Kusnadi EP; Pearson RB; Hannan RD; Haber M; Norris MD; Somers K; Henderson MJ
Cancer Res; 2020 Sep; 80(17):3706-3718. PubMed ID: 32651259
[TBL] [Abstract][Full Text] [Related]
19. MYCN and HIF-1 directly regulate
Hains AE; Uppal S; Cao JZ; Salwen HR; Applebaum MA; Cohn SL; Godley LA
Epigenetics; 2022 Dec; 17(13):2056-2074. PubMed ID: 35942521
[TBL] [Abstract][Full Text] [Related]
20. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
